Literature DB >> 9570576

Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation.

R Förster1, E Kremmer, A Schubel, D Breitfeld, A Kleinschmidt, C Nerl, G Bernhardt, M Lipp.   

Abstract

We describe the expression and regulation of the HIV-1 coreceptor CXCR4/fusin. Using anti-CXCR4 mAb, we demonstrate that this chemokine receptor is highly expressed on neutrophils, monocytes, B cells, and naive T cells among peripheral blood cells. In secondary lymphoid organs CXCR4 was found to be expressed on B cells. However, individual variations with regard to surface expression could be observed on T cells. Expression of the receptor is not confined to the cell surface, as large amounts of intracellular stores can be found on various leukocytes. Upon activation with phorbol esters the amount of cell surface-expressed CXCR4 on lymphocytes increases twofold within 30 s before it is completely down-regulated within the next 2 min. Incubation of leukocytes with stroma derived factor-1alpha, the natural ligand for CXCR4, induces down-regulation of up to 60% of surface-expressed receptors in a pertussis toxin-insensitive manner. Interestingly, receptor cross-linking caused by incubation of cells with anti-CXCR4 mAb triggers receptor trafficking, in that the receptor is rapidly internalized and recycled to the cell surface. Therefore, receptor internalization and recycling may regulate the functional interaction of the receptor with envelope proteins during an initial step of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570576

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

1.  Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5.

Authors:  S Shalekoff; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.

Authors:  Adam P Curnock; Marisa K Logan; Stephen G Ward
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 3.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells.

Authors:  Chad M Novince; Amy J Koh; Megan N Michalski; Julie T Marchesan; Jason Wang; Younghun Jung; Janice E Berry; Matthew R Eber; Thomas J Rosol; Russell S Taichman; Laurie K McCauley
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

Review 5.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

6.  CXCR4 signaling mediates morphine-induced tactile hyperalgesia.

Authors:  Natalie M Wilson; Hosung Jung; Matthew S Ripsch; Richard J Miller; Fletcher A White
Journal:  Brain Behav Immun       Date:  2010-12-28       Impact factor: 7.217

7.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

Authors:  Geoffrey L Uy; Michael P Rettig; Ibraheem H Motabi; Kyle McFarland; Kathryn M Trinkaus; Lindsay M Hladnik; Shashikant Kulkarni; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Ravi Vij; Peter Westervelt; John F DiPersio
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

8.  Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues.

Authors:  Chang-Zhi Dong; Shaomin Tian; Won-Tak Choi; Santhosh Kumar; Dongxiang Liu; Yan Xu; Xiaofeng Han; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-07-23       Impact factor: 3.162

Review 9.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

10.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.